Gomekli treats adults and children (≥2 years) with NF1-related plexiform neurofibromas that can’t be fully removed. It inhibits MEK enzymes to slow tumor growth and reduce tumor size.
Approval Date
11-Feb-25
NCE-1 Date
11-Feb-29
NCE Date
11-Feb-30
Commercial snapshot
Market performance & projections
Revenue ($M)
82
CAGR (%)
75.56%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
186
2027
385
2028
587
2029
779
2030
927
2031
1,054
2032
983
Molecule profile
Details & specifications
Molecule
Mirdametinib
Innovator
SPRINGWORKS THERAPEUTICS INC
Dosage Form
Oral Capsule And Oral Tablet, For Suspension
Strength
1 mg and 2 mg
Therapeutic Category
Anticancer
Usage
To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.